Farallon Capital Management LLC Invests $9.46 Million in Twist Bioscience Co. (NASDAQ:TWST)

Farallon Capital Management LLC purchased a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 192,000 shares of the company’s stock, valued at approximately $9,462,000. Farallon Capital Management LLC owned 0.33% of Twist Bioscience as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the second quarter valued at $43,000. Blue Trust Inc. grew its holdings in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $61,000. Nisa Investment Advisors LLC raised its holdings in Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after buying an additional 546 shares during the period. Finally, CWM LLC lifted its position in Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently commented on TWST shares. The Goldman Sachs Group raised their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Guggenheim began coverage on Twist Bioscience in a research note on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. TD Cowen boosted their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. Based on data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 842 shares of the company’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total transaction of $41,182.22. Following the completion of the transaction, the chief financial officer now directly owns 73,602 shares in the company, valued at approximately $3,599,873.82. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Emily M. Leproust sold 5,139 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the transaction, the chief executive officer now directly owns 499,593 shares of the company’s stock, valued at $19,948,748.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Laponis sold 842 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total transaction of $41,182.22. Following the completion of the sale, the chief financial officer now directly owns 73,602 shares of the company’s stock, valued at approximately $3,599,873.82. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,125 shares of company stock worth $664,784. 3.92% of the stock is currently owned by company insiders.

Twist Bioscience Price Performance

Shares of TWST opened at $45.29 on Tuesday. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90. The business’s fifty day moving average price is $47.05 and its 200 day moving average price is $43.14. The stock has a market capitalization of $2.64 billion, a PE ratio of -13.48 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. During the same period last year, the firm posted ($1.01) earnings per share. The company’s quarterly revenue was up 27.7% on a year-over-year basis. As a group, research analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.